公开(公告)号：WO2010097798A1

公开(公告)日：2010-09-02

申请号：PCT/IL2010/000164

申请日：2010-02-25

Applicant: URIFER LTD. ,  NIR, Uri ,  SHPUNGIN, Sally ,  YAFFE, Etai ,  COHEN, Moshe

Inventor： NIR, Uri ,  SHPUNGIN, Sally ,  YAFFE, Etai ,  COHEN, Moshe

IPC: C07D513/04 ,  A61P35/00

CPC classification number: C07D513/04

Abstract: The present invention is directed to novel heterocyclic compounds, their synthesis and pharmaceutical compositions comprising them for the treatment of disorders, in particular, cancer.

Abstract translation: 本发明涉及新颖的杂环化合物，它们的合成和药物组合物，其包含它们用于治疗疾病，特别是癌症。

公开(公告)号：WO2009019708A3

公开(公告)日：2009-05-14

申请号：PCT/IL2008001099

申请日：2008-08-10

Applicant: URIFER LTD ,  NIR URI ,  SHPUNGIN SALLY ,  YAFFE ETAI ,  COHEN MOSHE

Inventor： NIR URI ,  SHPUNGIN SALLY ,  YAFFE ETAI ,  COHEN MOSHE

IPC: A61K31/407 ,  A61K31/415 ,  A61K31/433 ,  A61K31/4706 ,  A61K31/496 ,  A61P35/00

CPC classification number: A61K31/407 ,  A61K31/415 ,  A61K31/433 ,  A61K31/4706 ,  A61K31/496 ,  C07D215/46 ,  C07D231/38 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: The invention provides a pharmaceutical composition comprising as an active component a compound of formula (I); wherein X and (ROn are as defined, and a physiological acceptable carrier. The invention also provides a method for treating cancer comprising administering to an individual in need of such treatment an effective amount of a pharmaceutical composition of the invention. The invention further provides use of a compound of formula (I) for the preparation of a medicament for the treatment of cancer.

Abstract translation: 本发明提供一种药物组合物，其包含式（I）化合物作为活性成分; 本发明还提供了一种治疗癌症的方法，包括对需要这种治疗的个体施用有效量的本发明的药物组合物，本发明还提供了使用本发明的药物组合物，其中X和 的式（I）化合物用于制备用于治疗癌症的药物。

公开(公告)号：WO2009019708A2

公开(公告)日：2009-02-12

申请号：PCT/IL2008/001099

申请日：2008-08-10

Applicant: URIFER LTD ,  NIR, Uri ,  SHPUNGIN, Sally ,  YAFFE, Etai ,  COHEN, Moshe

Inventor： NIR, Uri ,  SHPUNGIN, Sally ,  YAFFE, Etai ,  COHEN, Moshe

IPC: A61K31/407 ,  A61K31/433 ,  A61K31/496 ,  A61K31/415 ,  A61K31/4706

CPC classification number: A61K31/407 ,  A61K31/415 ,  A61K31/433 ,  A61K31/4706 ,  A61K31/496 ,  C07D215/46 ,  C07D231/38 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: The invention provides a pharmaceutical composition comprising as an active component a compound of formula (I); wherein X and (ROn are as defined, and a physiological acceptable carrier. The invention also provides a method for treating cancer comprising administering to an individual in need of such treatment an effective amount of a pharmaceutical composition of the invention. The invention further provides use of a compound of formula (I) for the preparation of a medicament for the treatment of cancer.

Abstract translation: 本发明提供了包含式（I）化合物作为活性组分的药物组合物; 其中X和（ROn如定义）和生理学上可接受的载体本发明还提供了用于治疗癌症的方法，其包括向需要这种治疗的个体施用有效量的本发明的药物组合物。 的式（I）化合物在制备用于治疗癌症的药物中的用途。

公开(公告)号：WO2007107991A1

公开(公告)日：2007-09-27

申请号：PCT/IL2007/000360

申请日：2007-03-20

Applicant: URIFER LTD. ,  NIR, Uri ,  PASDER, Orel ,  SHPUNGIN, Sally ,  YAFFE, Etai

Inventor： NIR, Uri ,  PASDER, Orel ,  SHPUNGIN, Sally ,  YAFFE, Etai

IPC: C12N15/11

CPC classification number: C12Y207/10002 ,  C12N9/1205 ,  C12N15/1137 ,  C12N2310/14

Abstract: The invention provides a method for modulating a Fer mediated pathway in a cell, for monitoring the effect of a Fer protein in a cell, for altering and inhibiting one or more effects of a Fer protein in a cell. The invention involves modulating, monitoring, altering or inhibiting any one or more or of the association of the Fer protein to PP1; the phosphorylation of PP1, the phosphatase activity of PP1, and the tumor suppressive activity of the retinoblastoma protein (RB). In a preferred embodiment of the invention, modulating a Fer mediated pathway in a cell, monitoring the effect of a Fer protein in a cell, for altering and inhibiting one or more effects of a Fer protein in a cell involves administrating to a cell compound having a molecular weight of up to 1000 Dalton capable of modulating, altering or inhibiting an effect of Fer. The invention further provides a method for determining whether a substance is capable of altering or inhibiting an effect of a Fer protein in a cell. The method includes presenting the substance to a first cell expressing an exogenous Fer gene or Fer cDNA; and measuring a rate of proliferation of the cell. A significant difference between the growth rate of the first cell and the growth rate of a second cell not expressing an exogenous Fer gene or Fer cDNA indicates that the substance is capable of altering a fer mediated pathway.

Abstract translation: 本发明提供了调节细胞中Fer介导的途径的方法，用于监测细胞中Fer蛋白的作用，以改变和抑制细胞中Fer蛋白的一种或多种作用。 本发明涉及调节，监测，改变或抑制Fer蛋白与PP1的任何一种或多种或结合; PP1的磷酸化，PP1的磷酸酶活性以及视网膜母细胞瘤蛋白（RB）的肿瘤抑制活性。 在本发明的优选实施方案中，调节细胞中Fer介导的途径，监测Fer蛋白在细胞中的作用，用于改变和抑制细胞中Fer蛋白的一种或多种作用，包括向具有 分子量高达1000道尔顿能够调节，改变或抑制Fer的作用。 本发明还提供了一种用于确定物质是否能够改变或抑制细胞中Fer蛋白的作用的方法。 该方法包括将物质呈递给表达外源Fer基因或Fer cDNA的第一个细胞; 并测量细胞增殖的速率。 第一细胞的生长速率与不表达外源性Fer基因或Fer cDNA的第二细胞的生长速率之间的显着差异表明该物质能够改变fer介导的途径。